Voya Investment Management LLC boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 139.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 250,281 shares of the life sciences company's stock after purchasing an additional 145,971 shares during the quarter. Voya Investment Management LLC owned approximately 0.17% of Illumina worth $68,497,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in ILMN. Signature Equity Partners LLC raised its holdings in shares of Illumina by 246.5% during the third quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company's stock valued at $41,000 after buying an additional 106 shares during the last quarter. Fiduciary Financial Advisors acquired a new position in shares of Illumina during the second quarter worth approximately $26,000. MCF Advisors LLC boosted its position in shares of Illumina by 172.4% during the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company's stock worth $28,000 after buying an additional 100 shares during the period. Keating Financial Advisory Services Inc. bought a new position in Illumina in the 2nd quarter worth approximately $32,000. Finally, Rakuten Securities Inc. bought a new position in Illumina in the 2nd quarter worth approximately $33,000. 89.42% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other news, Director Keith A. Meister sold 98,833 shares of Illumina stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the transaction, the director directly owned 208,826 shares in the company, valued at approximately $45,288,094.62. This trade represents a 32.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Scott D. Ericksen sold 267 shares of Illumina stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total value of $58,141.92. Following the transaction, the chief accounting officer owned 14,029 shares in the company, valued at approximately $3,054,955.04. This trade represents a 1.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,500,628 shares of company stock valued at $335,394,565 over the last 90 days. 2.90% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Several analysts have weighed in on ILMN shares. Stifel Nicolaus lifted their target price on Illumina from $155.00 to $225.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Citigroup boosted their price target on Illumina from $113.00 to $210.00 and gave the stock a "sell" rating in a research report on Monday, November 2nd. Sanford C. Bernstein reissued a "market perform" rating and issued a $215.00 price target on shares of Illumina in a research note on Friday, July 31st. Evercore reissued an "underperform" rating on shares of Illumina in a research note on Friday, October 30th. Finally, Argus raised their price target on Illumina from $180.00 to $235.00 and gave the company a "buy" rating in a report on Thursday, September 3rd. Nine research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, Illumina currently has an average rating of "Hold" and an average target price of $243.72.
Read Our Latest Stock Report on ILMN
Illumina Trading Up 3.7%
Shares of NASDAQ:ILMN opened at $210.01 on Thursday. The company has a 50 day moving average of $248.55 and a 200-day moving average of $180.47. The firm has a market cap of $31.75 billion, a P/E ratio of 38.59, a P/E/G ratio of 2.75 and a beta of 1.46. Illumina, Inc. has a twelve month low of $112.65 and a twelve month high of $309.35. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The business had revenue of $1.17 billion during the quarter, compared to analysts' expectations of $1.15 billion. During the same period last year, the firm posted $1.34 earnings per share. The business's revenue was up 4.2% on a year-over-year basis. As a group, analysts anticipate that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.
Illumina Company Profile
(
Free Report)
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company's technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
Further Reading
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.